Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [17]
- Comments [0]
- Validations
- Western blot [1]
- Immunoprecipitation [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 19602-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#19602-1-AP, RRID:AB_10642702
- Product name
- TRIP13 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TRIP13 antibody (Cat. #19602-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references ZFP541 and KCTD19 regulate chromatin organization and transcription programs for male meiotic progression.
An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.
TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.
TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.
Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).
Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma.
Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.
Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.
TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
SKP1 drives the prophase I to metaphase I transition during male meiosis.
TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.
TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
The PSMA8 subunit of the spermatoproteasome is essential for proper meiotic exit and mouse fertility.
TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Zhou X, Fang K, Liu Y, Li W, Tan Y, Zhang J, Yu X, Wang G, Zhang Y, Shang Y, Zhang L, Chen CD, Wang S
Cell proliferation 2024 Apr;57(4):e13567
Cell proliferation 2024 Apr;57(4):e13567
An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.
Dhasmana S, Dhasmana A, Rios S, Enriquez-Perez IA, Khan S, Afaq F, Haque S, Manne U, Yallapu MM, Chauhan SC
Computational and structural biotechnology journal 2023;21:5765-5775
Computational and structural biotechnology journal 2023;21:5765-5775
TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z, Li M, Zhang X, Rong X, Xu H
Oncology reports 2023 May;49(5)
Oncology reports 2023 May;49(5)
KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.
Lu S, Liu Y, Tian S, He Y, Dong W
Experimental cell research 2023 May 1;426(1):113564
Experimental cell research 2023 May 1;426(1):113564
TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.
Chotiner JY, Leu NA, Yang F, Cossu IG, Guan Y, Lin H, Wang PJ
bioRxiv : the preprint server for biology 2023 Dec 15;
bioRxiv : the preprint server for biology 2023 Dec 15;
Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).
Bossuyt X, Vulsteke JB, Van Elslande J, Boon L, Wuyts G, Willebrords S, Frans G, Geukens N, Carpentier S, Tejpar S, Wildiers H, Blockmans D, De Langhe E, Vermeersch P, Derua R
Autoimmunity reviews 2023 Apr;22(4):103288
Autoimmunity reviews 2023 Apr;22(4):103288
Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma.
Xu H, Ma Z, Mo X, Chen X, Xu F, Wu F, Chen H, Zhou G, Xia H, Zhang C
Journal of Cancer 2022;13(7):2226-2237
Journal of Cancer 2022;13(7):2226-2237
Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.
Rios Garcia M, Meissburger B, Chan J, de Guia RM, Mattijssen F, Roessler S, Birkenfeld AL, Raschzok N, Riols F, Tokarz J, Giroud M, Gil Lozano M, Hartleben G, Nawroth P, Haid M, López M, Herzig S, Berriel Diaz M
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022 Oct;9(29):e2104291
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022 Oct;9(29):e2104291
Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways.
Lan J, Huang J, Tao X, Gao Y, Zhang L, Huang W, Luo J, Liu C, Deng Y, Liu L, Liu X
Journal of cellular and molecular medicine 2022 May;26(9):2673-2685
Journal of cellular and molecular medicine 2022 May;26(9):2673-2685
TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH, Lei L, Fei LR, Huang WJ, Zheng YW, Yang MQ, Wang Z, Liu CC, Xu HT
Journal of molecular histology 2021 Feb;52(1):11-20
Journal of molecular histology 2021 Feb;52(1):11-20
SKP1 drives the prophase I to metaphase I transition during male meiosis.
Guan Y, Leu NA, Ma J, Chmátal L, Ruthel G, Bloom JC, Lampson MA, Schimenti JC, Luo M, Wang PJ
Science advances 2020 Mar;6(13):eaaz2129
Science advances 2020 Mar;6(13):eaaz2129
TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
Agarwal S, Behring M, Kim HG, Chandrashekar DS, Chakravarthi BVSK, Gupta N, Bajpai P, Elkholy A, Al Diffalha S, Datta PK, Heslin MJ, Varambally S, Manne U
Molecular oncology 2020 Dec;14(12):3007-3029
Molecular oncology 2020 Dec;14(12):3007-3029
TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.
Di S, Li M, Ma Z, Guo K, Li X, Yan X
Pathology, research and practice 2019 Jun;215(6):152415
Pathology, research and practice 2019 Jun;215(6):152415
TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, Peng W, Wang X, Chen F, Cui H
British journal of cancer 2019 Dec;121(12):1069-1078
British journal of cancer 2019 Dec;121(12):1069-1078
The PSMA8 subunit of the spermatoproteasome is essential for proper meiotic exit and mouse fertility.
Gómez-H L, Felipe-Medina N, Condezo YB, Garcia-Valiente R, Ramos I, Suja JA, Barbero JL, Roig I, Sánchez-Martín M, de Rooij DG, Llano E, Pendas AM
PLoS genetics 2019 Aug;15(8):e1008316
PLoS genetics 2019 Aug;15(8):e1008316
TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N, Yan L, Wu K, You W, Gong J, Hu L, Tan G, Chen H, Wang Z
Cell death & disease 2018 Mar 14;9(3):402
Cell death & disease 2018 Mar 14;9(3):402
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ
Nature communications 2014 Jul 31;5:4527
Nature communications 2014 Jul 31;5:4527
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Jurkat cells were subjected to SDS PAGE followed by western blot with 19602-1-AP(TRIP13 antibody) at dilution of 1:400
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TRIP13 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human TRIP13. This antibody recognizes human,mouse,rat antigen. The TRIP13 antibody has been validated for the following applications: ELISA, WB, IP analysis.
